Solid tumours with confirmed NTRK gene fusion - larotrectinib - initial authority application form (PB333)

Use this form to apply for initial PBS-subsidised treatment with larotrectinib for solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.

Page last updated: 1 June 2025.
QC 62814